Literature DB >> 22995045

Synthesis and GC-MS analysis of a series of homologs and regioisomers of 3,4-methylenedioxypyrovalerone (MDPV).

Younis F Hamad Abiedalla1, Karim Abdel-Hay, Jack DeRuiter, C Randall Clark.   

Abstract

A series of ten homologous and regioisomeric aminoketones related to the designer synthetic cathinone derivative MDPV were evaluated in this study. These compounds were prepared from a common precursor chemical, piperonal (3,4-methylenedioxybenzaldehyde). These aminoketones show major peaks in their mass spectra corresponding to the regioisomeric and homologous immonium cation fragments from the loss of the methylenedioxybenzoyl radical species. All ten compounds in this study show equivalent EI MS fragments for the 3,4-methylenedioxybenzoyl fragments (m/z 149) and the methylenedioxybenzene fragment at m/z 121. The m/z 149 results from ionization of the carbonyl oxygen followed by an alpha-cleavage fragmentation. The loss of CO from this ion yields the m/z 121 fragments common to all spectra. The regioisomeric aminoketones yield equivalent mass spectra including mass equivalent regioisomeric immonium cation base peaks. A subset of these compounds has the same molecular weight and almost identical mass spectra to that of the designer drug MDPV. An evaluation of the effects of homologation on gas chromatographic retention showed that addition of a methylene (CH(2)) in the nitrogen-containing ring increases retention more than the equivalent group added to the alkyl side-chain.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Year:  2012        PMID: 22995045     DOI: 10.1016/j.forsciint.2012.08.040

Source DB:  PubMed          Journal:  Forensic Sci Int        ISSN: 0379-0738            Impact factor:   2.395


  6 in total

1.  Synthetic cathinone MDPV downregulates glutamate transporter subtype I (GLT-1) and produces rewarding and locomotor-activating effects that are reduced by a GLT-1 activator.

Authors:  Ryan A Gregg; Callum Hicks; Sunil U Nayak; Christopher S Tallarida; Paul Nucero; Garry R Smith; Allen B Reitz; Scott M Rawls
Journal:  Neuropharmacology       Date:  2016-04-13       Impact factor: 5.250

2.  Dopamine D1-Like Receptor Agonist and D2-Like Receptor Antagonist (-)-Stepholidine Reduces Reinstatement of Drug-Seeking Behavior for 3,4-Methylenedioxypyrovalerone (MDPV) in Rats.

Authors:  Callum Hicks; Peng Huang; Linnet Ramos; Sunil U Nayak; Yohanka Caro; Allen B Reitz; Garry R Smith; David Y-W Lee; Scott M Rawls; Lee-Yuan Liu-Chen
Journal:  ACS Chem Neurosci       Date:  2018-04-06       Impact factor: 4.418

3.  Glutamate carboxypeptidase II (GCPII) inhibitor 2-PMPA reduces rewarding effects of the synthetic cathinone MDPV in rats: a role for N-acetylaspartylglutamate (NAAG).

Authors:  Callum Hicks; Ryan A Gregg; Sunil U Nayak; Lee Anne Cannella; Giana J Schena; Christopher S Tallarida; Allen B Reitz; Garry R Smith; Scott M Rawls
Journal:  Psychopharmacology (Berl)       Date:  2017-03-01       Impact factor: 4.530

4.  Comparing rewarding and reinforcing properties between 'bath salt' 3,4-methylenedioxypyrovalerone (MDPV) and cocaine using ultrasonic vocalizations in rats.

Authors:  Steven J Simmons; Ryan A Gregg; Fionya H Tran; Lili Mo; Eva von Weltin; David J Barker; Taylor A Gentile; Lucas R Watterson; Scott M Rawls; John W Muschamp
Journal:  Addict Biol       Date:  2016-12-01       Impact factor: 4.280

Review 5.  Emerging drugs of abuse: current perspectives on substituted cathinones.

Authors:  Magalie Paillet-Loilier; Alexandre Cesbron; Reynald Le Boisselier; Joanna Bourgine; Danièle Debruyne
Journal:  Subst Abuse Rehabil       Date:  2014-05-26

6.  3,4-Methylenedioxypyrovalerone (MDPV) Sensing Based on Electropolymerized Molecularly Imprinted Polymers on Silver Nanoparticles and Carboxylated Multi-Walled Carbon Nanotubes.

Authors:  Rosa A S Couto; Constantino Coelho; Bassim Mounssef; Sara F de A Morais; Camila D Lima; Wallans T P Dos Santos; Félix Carvalho; Cecília M P Rodrigues; Ataualpa A C Braga; Luís Moreira Gonçalves; M Beatriz Quinaz
Journal:  Nanomaterials (Basel)       Date:  2021-02-01       Impact factor: 5.076

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.